Company: IMRX
Filing Date: 2025-09-25
Form Type: 424B5
Source: 0001104659-25-093438
Chunk: 30

Company: Immuneering Corp
Filing Date: 2025-09-25
Form: 424B5
Chunk 30
---
,500,000 | ​ | ​ | ​ | ​             | $ |  12,075,000 | ​ | ​ |
| Proceeds, before expenses, to us                        | ​ | ​ | ​         | $ | 8.6762 | ​ | ​ | ​ | ​           | $ | 164,500,006 | ​ | ​ | ​ | ​             | $ | 189,175,006 | ​ | ​ |

We estimate expenses payable by us in connection with this offering, other than the underwriting discounts and commissions referred to above, will be approximately $450,000. We have agreed to reimburse the underwriters for expenses relating to clearance of this offering with the Financial Industry Regulatory Authority up to $35,000. Leerink Partners LLC and Oppenheimer & Co. Inc. are acting as placement agents in connection with the concurrent private placement and will receive 6.0% of the aggregate gross proceeds from the sale of the securities in the concurrent private placement. Option to Purchase Additional Shares We have granted the underwriters the option to purchase up to additional shares of our Class A common stock from us at the public offering price, less underwriting discounts and commissions. The underwriters may exercise this right at any time, in whole or in part, within 30 days following the date of this prospectus supplement. If the underwriters exercise this option, each underwriter will be obligated, subject to the conditions contained in the underwriting agreement, to purchase a number of additional shares proportionate to that underwriter’s initial amount reflected in the above table Listing Our common stock is listed on The Nasdaq Global Market (“Nasdaq”) under the trading symbol “IMRX”. No Sales of Similar Securities We, our directors and officers have agreed that, without the prior written consent of the underwriters, they will not, and will not publicly disclose an intention to, during the period ending 60 days after the date of this prospectus supplement (the “restricted period”): (1) offer, pledge, sell, contract to sell, sell any option or contract to purchase, purchase any option or contract to sell, grant any option, right or warrant to purchase, lend, or otherwise transfer or dispose of, directly or indirectly, any common stock or any securities convertible into or exercisable or exchangeable for common stock, (2) enter into any swap or other arrangement that transfers to another, in whole or in part, any of the economic consequences of ownership of the common stock, or (